REG - Aptamer Group PLC - Placing and Subscription, PDMR Dealing and TVR

AptamerAnnouncement

19/09/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230919:nRSS9603Ma&default-theme=true

RNS Number : 9603M  Aptamer Group PLC  19 September 2023

19 September 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Placing and Subscription to raise £310,772

 

PDMR Dealing

 

Total Voting Rights

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces that it
has raised £310,772 through the issue of 28,251,956 new Ordinary Shares by
way of a subscription and a placing by Turner Pope to certain existing
shareholders at 1.1p per share (the "Issue Price") (together, the
"Fundraise").

 

The Fundraise was initiated following approaches from existing non-UK
shareholders who could not be contacted in time to participate in the August
2023 fundraise and extended to take advantage of demand from other existing
shareholders using the Company's remaining net authorised unissued share
capital.

 

The Fundraise includes a subscription by Dr Adam Hargreaves, a non-executive
director of the Company, for 5,000,000 new Ordinary Shares for a total
investment of £55,000.  Following this further investment, Dr Hargreaves is
now interested in 22,500,000 Ordinary Shares representing 4.81 per cent of the
enlarged issued share capital.

 

In addition, an existing investor, Mr Nicholas Slater, is investing £50,000
in the Fundraise for 4,545,454 new Ordinary Shares, taking his holding to
26,045,454 Ordinary Shares representing 5.57% of the enlarged issued share
capital.

 

The net proceeds will be ringfenced to support research and development
(R&D) activities within the business, including the ongoing process
improvements. R&D work was reduced as part of the Company's new strategy
to support cost-cutting in August. While higher-risk development activities
will still aim to be funded by grants, the new funds will enable internal
validation of the technology in key focus areas.

 

Total Voting Rights

 

Application for the admission of the new Ordinary Shares to trading on AIM
("Admission") has been made and Admission is expected on Monday, 25 September
2023, following which the total number of shares in issue and total voting
rights will be 467,343,673.  The Group does not hold any shares in treasury
and, therefore, the above figure may be used by shareholders as the
denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in the
Company.

 

 

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018.

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/)  develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Adam Hargreaves

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director - PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Aptamer Group plc

 b)   LEI                                                          213800Y4XGH3WJNBE686

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BNRRP542

 b)   Nature of the transaction                                    Acquisition of shares

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   1.1p      5,000,000

 

 d)   Aggregated information                                       n/a

      - Aggregated volume
      - Price

 e)   Date of the transaction                                      19 September 2023

 f)   Place of the transaction                                     Off market

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

 

19 September 2023

f)

 

Place of the transaction

 

Off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESFLFDUEDSEDU